Ironwood Pharmaceuticals Inc
IRWD0.748USD
-0.023-2.99%
交易中 （美東）報價延遲15分鐘
121.08M總市值
虧損本益比TTM
關於 Ironwood Pharmaceuticals Inc 公司
Ironwood Pharmaceuticals, Inc. 是一家胃腸道 (GI) 醫療保健公司，致力於推進胃腸道疾病的治療並重新定義胃腸道患者的護理標準。該公司致力於開發 LINZESS（利那洛肽），用於治療成人便祕性腸易激綜合徵 (IBS-C) 或慢性特發性便祕 (CIC)。利那洛肽還獲准用於治療 6-17 歲兒童患者的功能性便祕。該公司正在推進阿普拉魯肽，這是一種長效合成胰高血糖素樣肽-2 (GLP-2) 類似物，正在開發用於治療罕見胃腸道疾病，包括伴有腸衰竭的短腸綜合徵 (SBS-IF) 以及幾種早期資產。該公司正在推進 IW-3300（一種 GC-C 激動劑）的研發，用於治療內臟疼痛病症，例如間質性膀胱炎/膀胱疼痛綜合徵 (IC/BPS) 和子宮內膜異位症。該公司還在開發 CNP-104，用於治療 PBC（一種罕見的針對肝臟的自身免疫性疾病）。
公司簡介
公司代碼IRWD
公司名稱Ironwood Pharmaceuticals Inc
上市日期Feb 03, 2010
CEOMr. Thomas A. (Tom) Mccourt
員工數量253
證券類型Ordinary Share
年結日Feb 03
公司地址100 Summer Street, Suite 2300
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02110
電話16176217722
網址https://www.ironwoodpharma.com/
公司代碼IRWD
上市日期Feb 03, 2010
CEOMr. Thomas A. (Tom) Mccourt
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
246.38K
+39.05%
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
233.23K
+23.91%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
Mr. Jon R. Duane
Mr. Jon R. Duane
Independent Director
Independent Director
190.34K
+30.96%
Mr. John Minardo
Mr. John Minardo
Senior Vice President, Chief Legal Officer, Secretary
Senior Vice President, Chief Legal Officer, Secretary
175.40K
-23.97%
Ms. Marla L. Kessler
Ms. Marla L. Kessler
Independent Director
Independent Director
165.88K
+37.23%
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
117.94K
+61.69%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas A. (Tom) Mccourt
Mr. Thomas A. (Tom) Mccourt
Chief Executive Officer, Director
Chief Executive Officer, Director
1.37M
+62.57%
Dr. Mark G. Currie, Ph.D.
Dr. Mark G. Currie, Ph.D.
Independent Director
Independent Director
613.42K
+7.92%
Dr. Michael Shetzline, M.D., Ph.D.
Dr. Michael Shetzline, M.D., Ph.D.
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
Senior Vice President, Chief Medical Officer, Head of Research and Drug Development
324.29K
-17.25%
Dr. Alexander J. (Alex) Denner, Ph.D.
Dr. Alexander J. (Alex) Denner, Ph.D.
Independent Director
Independent Director
246.38K
+39.05%
Mr. Andrew Dreyfus
Mr. Andrew Dreyfus
Independent Director
Independent Director
233.23K
+23.91%
Ms. Julie H. Mchugh
Ms. Julie H. Mchugh
Independent Chairman of the Board
Independent Chairman of the Board
208.84K
+27.47%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月22日 週四
更新時間: 5月22日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Sarissa Capital Management, L.P.
10.13%
The Vanguard Group, Inc.
10.01%
Armistice Capital LLC
8.47%
BlackRock Institutional Trust Company, N.A.
6.65%
Renaissance Technologies LLC
6.14%
Other
58.60%
持股股東
持股股東
佔比
Sarissa Capital Management, L.P.
10.13%
The Vanguard Group, Inc.
10.01%
Armistice Capital LLC
8.47%
BlackRock Institutional Trust Company, N.A.
6.65%
Renaissance Technologies LLC
6.14%
Other
58.60%
股東類型
持股股東
佔比
Hedge Fund
44.50%
Investment Advisor
29.11%
Investment Advisor/Hedge Fund
17.10%
Research Firm
6.16%
Individual Investor
2.93%
Pension Fund
0.59%
Venture Capital
0.34%
Bank and Trust
0.30%
Sovereign Wealth Fund
0.29%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
580
164.05M
101.38%
-34.03M
2025Q1
598
162.94M
100.73%
-39.13M
2024Q4
595
170.54M
106.57%
-31.05M
2024Q3
583
171.68M
107.49%
-32.57M
2024Q2
576
178.76M
112.46%
-25.68M
2024Q1
583
179.31M
112.83%
-3.43M
2023Q4
563
172.78M
110.50%
-13.64M
2023Q3
560
170.59M
109.32%
-22.08M
2023Q2
550
173.56M
111.70%
-13.28M
2023Q1
553
173.35M
111.59%
-16.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Sarissa Capital Management, L.P.
16.39M
10.13%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
16.20M
10.01%
+995.30K
+6.55%
Jun 30, 2025
Armistice Capital LLC
13.70M
8.47%
+4.23M
+44.70%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.76M
6.65%
-10.57M
-49.54%
Mar 31, 2025
Renaissance Technologies LLC
9.94M
6.14%
+874.25K
+9.64%
Mar 31, 2025
Braidwell LP
6.62M
4.09%
+1.18M
+21.73%
Mar 31, 2025
Millennium Management LLC
6.36M
3.93%
+4.18M
+191.67%
Mar 31, 2025
Kynam Capital Management LP
5.82M
3.6%
+1.14M
+24.27%
Mar 31, 2025
LSV Asset Management
4.00M
2.47%
-83.70K
-2.05%
Mar 31, 2025
Jane Street Capital, L.L.C.
3.51M
2.17%
+3.09M
+740.46%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Acquirers Small and Micro Deep Value ETF
1%
Vanguard US Value Factor ETF
0.17%
Amplify Etho Climate Leadership U.S. ETF
0.15%
Inspire Small/Mid Cap ESG ETF
0.09%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.05%
iShares Micro-Cap ETF
0.03%
Principal U.S. Small-Cap ETF
0.02%
Schwab Fundamental U.S. Small Company ETF
0.02%
WisdomTree US SmallCap Fund
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
查看更多
Acquirers Small and Micro Deep Value ETF
佔比1%
Vanguard US Value Factor ETF
佔比0.17%
Amplify Etho Climate Leadership U.S. ETF
佔比0.15%
Inspire Small/Mid Cap ESG ETF
佔比0.09%
SPDR SSGA US Small Cap Low Volatility Index ETF
佔比0.05%
iShares Micro-Cap ETF
佔比0.03%
Principal U.S. Small-Cap ETF
佔比0.02%
Schwab Fundamental U.S. Small Company ETF
佔比0.02%
WisdomTree US SmallCap Fund
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
